The Landscape of PARP Inhibitors in Solid Cancers

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• PARP inhibitors exhibit preclinical efficacy in homologous recombination (HR) deficient models.
• Synthetic lethality between HR defects and PARP inhibition drives clinical trials.
• Significant responses observed in breast and ovarian cancers with HR defects.

Purpose of the Study:

• To review the efficacy of PARP inhibitors (PARPi) in solid tumors with HR defects.
• To explore the potential of PARPi in combination with other therapeutic agents.

Main Methods:

• Review of clinical trial data for PARPi in various solid tumors.
• Analysis of preclinical studies on PARP inhibition and HR defects.
• Evaluation of combination therapy strategies involving PARPi.

Main Results:

• PARPi have demonstrated significant responses in breast, ovarian, prostate, and pancreatic cancers with HR defects.
• Several PARP inhibitors are now clinically available.
• Combination therapies, including with immune checkpoint inhibitors, show potential for improved survival.

Conclusions:

• PARP inhibitors are effective treatments for HR-deficient solid tumors.
• Expanding use of PARPi to prostate and pancreatic cancers is supported by clinical data.
• Combination strategies hold promise for enhancing patient outcomes.